Journal
JOURNAL OF NEUROIMMUNOLOGY
Volume 240, Issue -, Pages 58-64Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jneuroim.2011.09.012
Keywords
Carbenoxolone; IL-23 p19; IL-17; Experimental autoimmune encephalomyelitis; Protein phosphatase 2A
Categories
Funding
- National Institute of Biomedical Innovation (NIBIO)
- global COE from the Ministry of Education, Culture, Sports, Science and Technology of Japan
- Ministry of Health, Labour and Welfare of Japan
- New Energy and Industrial Technology Development Organization (NEDO) of Japan
- Grants-in-Aid for Scientific Research [22790816] Funding Source: KAKEN
Ask authors/readers for more resources
Carbenoxolone (CBX) is a widely used gap-junction inhibitor. We have previously shown that treatment with CBX significantly delayed the onset of experimental autoimmune encephalomyelitis (EAE). However, the mechanism by which CBX delays the onset of EAE remains to be elucidated. Here, we show that CBX specifically inhibits the production of IL-23 by dendritic cells (DCs) and microglia in vitro. CBX treatment significantly reduced the population of Th17 cells in EAE mice. Furthermore, CBX downregulated the expression of IL-23 p19 via increased production of protein phosphatase 2A (PP2A). Thus, CBX may be an effective therapeutic strategy against Th17-mediated autoimmune diseases, such as multiple sclerosis. (C) 2011 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available